Fresenius Medical Care Sees US Plans for Kidney Disease as Positive
Thousands of end stage renal disease experts turn to Renal Therapies Group for pharmaceuticals and the most prescribed technologies in the industry.
Power your practice with our resources. We're here to help support your patients and your thriving practice.
Every day, we’re working tirelessly to transform the future of healthcare. Because every patient deserves treatment as strong as they are.
Browser Upgrade Recommended: Our website has detected that you are using a version of Internet Explorer that will prevent you from accessing certain features on FMCNA.com. We strongly recommend that you use a different browser to optimize your viewing experience. Supported browsers include Chrome, Edge, Firefox, and Safari.
Bloomfield-based Cigna and a Massachusetts health company have launched a national program aimed at lowering the cost of care for people undergoing dialysis for end-stage kidney disease.
The health insurer and Waltham, Mass.-based Fresenius Medical Care North America (FMCNA), which specializes in care for people with renal and other chronic conditions, announced the partnership Tuesday.
The program is part of Cigna Collaborative Care, a value-based model that uses incentives to engage healthcare providers. The new initiative is Cigna’s first value-based arrangement with kidney disease specialists.
Under the new initiative, Fresenius Medical Care will continue to be paid for the kidney dialysis services it provides to its Cigna patients, while its affiliate, insurer Fresenius Health Partners, will assume separate responsibility to manage medical costs and improve patient outcomes.
Read full story at the HartfordBusiness.com.